Beam Therapeutics Inc. (BEAM): Price and Financial Metrics

Beam Therapeutics Inc. (BEAM): $23.90

0.41 (-1.69%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add BEAM to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#86 of 362

in industry

BEAM Price/Volume Stats

Current price $23.90 52-week high $49.50
Prev. close $24.31 52-week low $16.95
Day low $23.64 Volume 4,536,900
Day high $24.94 Avg. volume 1,442,018
50-day MA $32.81 Dividend yield N/A
200-day MA $27.51 Market Cap 1.95B

BEAM Stock Price Chart Interactive Chart >


Beam Therapeutics Inc. (BEAM) Company Bio


Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.


BEAM Latest News Stream


Event/Time News Detail
Loading, please wait...

BEAM Latest Social Stream


Loading social stream, please wait...

View Full BEAM Social Stream

Latest BEAM News From Around the Web

Below are the latest news stories about BEAM THERAPEUTICS INC that investors may wish to consider to help them evaluate BEAM as an investment opportunity.

2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street

Wall Street is uber-bullish on these two Ark Invest holdings.

Yahoo | December 27, 2023

11 Most Promising Biotech Stocks to Buy According to Analysts

In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Buy According to Analysts. The biotech industry is making a resurgence […]

Yahoo | December 15, 2023

The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics

bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog.

Yahoo | December 14, 2023

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company’s board of directors. “Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry’s premier autologous cell therapy comp

Yahoo | December 14, 2023

Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?

Beam Therapeutics Inc. (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 8, 2023

Read More 'BEAM' Stories Here

BEAM Price Returns

1-mo -31.62%
3-mo 0.89%
6-mo 25.13%
1-year -23.30%
3-year -67.79%
5-year N/A
YTD -12.20%
2023 -30.40%
2022 -50.92%
2021 -2.39%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!